TX-MAVENIR
6.12.2023 16:20:38 CET | Business Wire | Press release
Pardeep Kohli, CEO of Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, has today welcomed the new ranking by global technology intelligence company ABI Research that recognizes Mavenir as the leading vendor in Open Radio Access Network (Open RAN) solutions. In ABI Research’s detailed and independent Competitive Assessment vendor matrix, Mavenir tops all three ranking categories – market leadership, innovation and implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206233989/en/
ABI Research Open RAN Vendor Ranking November 2023 (Graphic: Business Wire)
Mavenir is classed as the leading innovator in the Open RAN space with an impressive score of 81.5 out of 100, while its achievement of 84.5 out of 100 in the implementation criteria reflects Mavenir’s central role in accelerating Open RAN deployments globally. These key rankings position Mavenir as the overall global market leader for Open RAN in the ABI Research assessment framework.
Commenting on Mavenir’s stand-out performance in the global vendor analysis, Mavenir CEO Pardeep Kohli said: “I wholeheartedly welcome this recognition of our market leadership by ABI Research, following a robust and impartial assessment of both new and incumbent players. This pole-position ranking – delivered through ABI Research’s respected and transparent process – is a significant endorsement of our dedicated mission to create the market conditions, forge the industry partnerships and deliver the technology innovation to accelerate ubiquitous and large-scale Open RAN deployments, generating powerful gains for operators and users alike.”
Using a rigorous and thorough assessment framework, ABI Research has evaluated the leading Open RAN vendors to provide a comprehensive and authoritative picture of the competitive dynamics of the Open RAN vendor ecosystem. The core areas of analysis span ten criteria, segmented across innovation and implementation clusters – including R&D activities, O-RAN Alliance contributions, support for mMIMO, recent commercial momentum, product portfolio, geographical coverage, partnerships and memberships, PoCs/trials/testing, energy efficiency commitments and brownfield deployments – concluding with an in-depth profile of the implementation and innovation strategies of the major market players.
Saqlain Ali, Senior Analyst at ABI Research remarked: “Mavenir ranked overall leader in the competitor ranking and earned the top spots for both innovation and implementation. Mavenir has demonstrated its role as a leading Open RAN vendor due to its end-to-end cloud-native software and hardware and O-RAN Alliance-compliant solutions.”
He added: “Mavenir has made significant efforts to accelerate Open RAN deployments in partnerships with other mobile, chipset vendors, and cloud providers to validate its Open RAN portfolio for multi-vendor deployments. Mavenir’s customer base is diverse, with Mavenir serving 300+ CSPs in more than 120 countries.”
The report authors highlight several areas where Mavenir is demonstrating its role as a leading industry innovator in the Open RAN domain, including its provision of end-to-end cloud-native software and hardware solutions with a comprehensive portfolio covering the core, edge and Open RAN. Further emphasized in the framework are Mavenir’s open and fully virtualized RAN (vRAN), its O-RAN Alliance-compliant solution designed to support Open RAN Functional Split (FS) options, plus Mavenir’s OpenBeam™ mMIMO portfolio, which supports both the 3rd Generation Partnership Project (3GPP) and O-RAN Alliance-compliant radios.
Mavenir’s clear commercial momentum during 2023 is a key factor in its top-ranking performance, including its announcement of multiple successful trials and new strategic partnerships with CSPs, cloud providers, and chipset vendors. The assessors particularly note the expansion of Mavenir’s geographical coverage in supporting major mobile operators with Open RAN deployment. Finally, the report draws attention to the considerable breadth of Mavenir’s partner ecosystem, plus its active collaboration with cloud providers, chipset vendors, mobile vendors, and operators to perform Open RAN integration and interoperability testing.
Notes to editors:
- ABI Research, Open RAN Vendor Assessment: Mavenir
© 2023 ABI Research. Distributed with permission of ABI Research. ABI Research Competitive Ranking, Open RAN Portfolio: November 2023
About ABI Research:
ABI Research is a global technology intelligence firm delivering actionable research and strategic guidance to technology leaders, innovators, and decision makers around the world. Our research focuses on the transformative technologies that are dramatically reshaping industries, economies, and workforces today.
For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231206233989/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom